Recently, the argument that “the Japanese government has paid for Japanese companies to withdraw from China” has triggered discussions. In an interview with the surging news (www.thepaper.cn), the Japanese company Fujifilm stated that Fujifilm has no plans to transfer or withdraw production from China, and Fujifilm has been constantly seeking business opportunities to contribute to China’s social progress and industrial development. .
In early April, Japan announced the launch of the “Industrial Chain Reform” plan to encourage companies with high supply chain dependence overseas to relocate production bases to the country, especially for masks, Subsidies will be given to the relocation of anti-epidemic supplies factories such as disinfectants, protective clothing, ventilators, and artificial lungs.
As a diversified company that has successfully transformed from the traditional film field to cover high-performance materials, medical health, optical equipment and other fields, medical products are the backbone of today’s Fujifilm One of the industries.
The anti-influenza drug “Avigan” (Fapiravir), which is currently considered to be effective against the new coronavirus, was developed by Fujifilm’s “Toyama Chemical”. The United States initiated clinical trials for the treatment of new coronavirus. Fujifilm recently said that it will expand Toyama Chemical’s production capacity and increase production of piravir.
Fujifilm (China) told reporters that the company has no plans to transfer or withdraw production from China. Fujifilm ’s future development in China will focus on medical health and New core manufacturing industries, such as electric vehicles, the environment, and information and communication technology (ICT).
The chief representative of the Japan Trade Promotion Agency Shanghai Representative Office told the reporter that according to their latest survey of 710 Japanese companies in East China, about 90% of the companies said they did not Change the supply chain or stronghold plan.